$APTOF

PLATZER ERICH sold (to issuer) $2K of APTOF

PLATZER ERICH sold (to issuer) 1,122 shares of Aptose Biosciences Inc. (APTOF) at $1.72 on 2026-06-30.

Original reporting
SEC EDGAR · PLATZER ERICH
Published Jul 1, 2026, 8:55 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 1, 2026, 9:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$APTOF
Bearish
medium confidence
Mentioned
$APTOF
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$APTOFBearishLow
01

Why it matters

Because the transaction is small and not tied to a disclosed corporate event, the main tradable angle is short-term sentiment/positioning around insider selling rather than fundamental repricing.

02

Market read

Traders may monitor for follow-on insider activity, but this specific disclosure alone is unlikely to drive a major repricing.

03

What to watch

No role/position is provided in the scrape, and the transaction code indicates sale-to-issuer mechanics; without context, interpreting it as a strong signal is risky.

Relevance 3/10Novelty 3/10Timing: SEC Form 4 filed July 1, covering a June 30 insider sale.

Background

The filing is an SEC Form 4 insider transaction for Aptose Biosciences, reporting a sale to the issuer by Erich Platzer on 2026-06-30.

Company-level read

Ticker impact

$APTOFBearishMedium confidence
Context

Aptose Biosciences insider Erich Platzer sold 1,122 shares to the issuer at $1.7200 on 2026-06-30, leaving 0 shares.

Expected impact

Low likelihood of a sustained move; any reaction is likely limited to short-term sentiment/positioning.

Evidence & confidence

Form 4 is primary-source and time-stamped, but the transaction is modest (~$1.93k) and explicitly not under a pre-arranged 10b5-1 plan, which can increase interpretive sensitivity without implying a material corporate event.

Market effects

Minimal read-through for biotech/clinical-stage peers; this is a single small insider transaction.

No clear regional spillover implied by the filing.

No broader global market linkage indicated.

Counterpoint

The sale is to the issuer (often buyback/administrative mechanics) and the small size may reflect liquidity/tax rather than a bearish view.

Key entities

  • Aptose Biosciences Inc.

    Subject of the Form 4 insider transaction; ticker shown as APTOF in the filing.

  • PLATZER ERICH

    Reported insider who sold 1,122 shares to the issuer at $1.7200/share.

Related articles

$APTOFMed

Aptose Biosciences Inc. (APTOF): Completion of Acquisition or Disposition of Assets

Aptose Biosciences Inc. (APTOF) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. 8-K false 0000882361 0000882361 2026-06-30 2026-06-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30,